Endocrinological effects of treatment with high doses of medroxyprogesterone acetate in patients with renal or prostatic adenocarcinoma.
Tomic
R
R
Department of Urology & Andrology, University of Umeå, Sweden.
Ljungberg
B
B
Damber
J E
JE
D000230:Adenocarcinoma / Q000188:drug therapy*; D000728:Androgens / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012738:Sex Hormone-Binding Globulin / Q000187:drug effects
D000728:Androgens; D000970:Antineoplastic Agents; D012738:Sex Hormone-Binding Globulin; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone